The JPMorgan Healthcare Conference typically frontloads the conference putting most, if not all, of the heavy hitters' presentations in the first couple of days of the four-day event.
So, it's no surprise that a company the size of Dendreon was pulling up the rear or, if you want to think it was placed towards the end to keep people around, batting cleanup at the conference when it presented today.
Because I did a live interview on Tuesday from JPM with DNDN CEO Dr. Mitchell Gold I didn't even bother to listen to the webcast of his presentation this afternoon. That'll teach me. I mean, only two days ago he affirmed that the results of the oh-so-crucial test of the company's prostate cancer treatment were still expected around mid-year.
But today he told investors that the final analysis is now expected by April of this year.
You can check it out for yourself on Dendreon's Webcast.
Dr. Gold said the company "recently received notice" that the clinical trial had hit a certain milestone and that, as a result, the ultimate analysis is now expeted sooner rather than later. "This is a near-term event for the company," he said. "So, it's a very exciting time for us and it's a very exciting time for patients."
The news pulled the sometimes volatile stock up off of its lows and it closed a penny higher on more than double its average daily volume.
Questions? Comments? Pharma@cnbc.com